Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hepatitis C

Free Subscription Articles published in PLoS One Retrieve available abstracts of 91 articles: HTML format

Single Articles

January 2025
1. MOONEN CPB, Brouwers EEHG, Hoebe CJPA, Dukers-Muijrers NHTM, et al
   Reaching Syrian migrants through Dutch municipal registries for hepatitis B and C point-of-care testing.
   PLoS One. 2025;20:e0316726.
   PubMed     Abstract available
   
   
   
2. ADJEI-GYAMFI S, Asirifi A, Asobuno C, Korang FK, et al
   Knowledge and occupational practices of beauticians and barbers in the transmission of viral hepatitis: A mixed-methods study in Volta Region of Ghana.
   PLoS One. 2025;20:e0306961.
   PubMed     Abstract available
   
   
   
3. PATIL A, Vidhate P, Patil S, Rao A, et al
   Looking back into the Hepatitis C Virus epidemic dynamics from Unnao, India through phylogenetic approach.
   PLoS One. 2025;20:e0317705.
   PubMed     Abstract available
   
   
   
4. ZUBAIR S, Parvaiz F, Abualait T, Al-Regaiey K, et al
   Computational design of multi-epitope vaccine against Hepatitis C Virus infection using immunoinformatics techniques.
   PLoS One. 2025;20:e0317520.
   PubMed     Abstract available
   
   
   
5. 
   Expression of Concern: Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture.
   PLoS One. 2025;20:e0319262.
   PubMed    
   
   
   
6. ELIAH DT, Chamba NG, Sadiq AM, Mwasamwaja AO, et al
   Seroprevalence and associated factors for hepatitis B and hepatitis C viral infection among patients with diabetes mellitus in Northern Tanzania.
   PLoS One. 2025;20:e0319198.
   PubMed     Abstract available
   
   
   
7. TORIU N, Sato Y, Kamimura H, Yoshikawa T, et al
   Aligning cellular and molecular components in age-dependent tertiary lymphoid tissues of kidney and liver.
   PLoS One. 2025;20:e0311193.
   PubMed     Abstract available
   
   
   
8. 
   Expression of Concern: Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.
   PLoS One. 2025;20:e0320610.
   PubMed    
   
   
   
9. PAWLOWSKI T, Radkowski M, Perlejewski K, Szymanska B, et al
   Direct-acting antivirals (DAA) positively affect depression and cognitive function in patients with chronic hepatitis C.
   PLoS One. 2025;20:e0320221.
   PubMed     Abstract available
   
   
   
10. LI J, He J, Yang G, Cao Z, et al
    Influencing factors of HCV testing willingness among men who have sex with men in China: A structural equation modeling analysis.
    PLoS One. 2025;20:e0321469.
    PubMed     Abstract available
    
    
    
11. BAKIC M, Stevanovic J, Milic M, Galic I, et al
    Factors associated with the prevalence of viral hepatitis B and C among prisoners: Results of two consecutive national surveys in Montenegro.
    PLoS One. 2025;20:e0321464.
    PubMed     Abstract available
    
    
    
12. FOSU PK, Hoor GT, Adjei CA, Atibila F, et al
    Prevalence of Hepatitis C viral infection in Ghana: A systematic review and meta-analysis protocol.
    PLoS One. 2025;20:e0321483.
    PubMed     Abstract available
    
    
    
13. BAHARUDIN MH, Mokhtar SA, Azman AZF, Mohd Nazan AIN, et al
    Utilizing Theory of Planned Behaviour to increase intention to participate in hepatitis C treatment therapy among Methadone maintenance therapy clients (MMT) in Malaysia: A cluster randomised control trial.
    PLoS One. 2025;20:e0324718.
    PubMed     Abstract available
    
    
    
14. SEGHIERI C, Ceccarelli L, Tortu C, Tavoschi L, et al
    Evaluating the effectiveness of a population-level health intervention to increment HCV treatment coverage in tuscany region, Italy: An interrupted time series analysis.
    PLoS One. 2025;20:e0306733.
    PubMed     Abstract available
    
    
    
15. WOYTOWICH D, McIntyre AF, Solomon H, Hanunka B, et al
    Local data for local programming: Results from an HIV biobehavioral survey among people who inject drugs in Livingstone, Lusaka, and Ndola, Zambia, 2021.
    PLoS One. 2025;20:e0323919.
    PubMed     Abstract available
    
    
    
16. PARK YJ, Yi KY, Woo HY, Heo J, et al
    Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study.
    PLoS One. 2025;20:e0324019.
    PubMed     Abstract available
    
    
    
17. CEPEDA J, Atta M, Zook K, Landry M, et al
    Longitudinal effect of HCV cure on markers of kidney disease.
    PLoS One. 2025;20:e0325699.
    PubMed     Abstract available
    
    
    
18. TUSHER EH, Ismail MA, Akib A, Gabralla LA, et al
    Comparative investigation of bagging enhanced machine learning for early detection of HCV infections using class imbalance technique with feature selection.
    PLoS One. 2025;20:e0326488.
    PubMed     Abstract available
    
    
    
19. HAGE K, Hamusonde K, van Santen DK, Newsum AM, et al
    Longitudinal trajectories of sexual behavior and incident hepatitis C reinfection among men who have sex with men with HIV.
    PLoS One. 2025;20:e0326094.
    PubMed     Abstract available
    
    
    
20. SILVA FILHO GFD, Milhomem AB, Diniz E Silva BV, Santos KCD, et al
    Taking the opportunity of COVID testing to screen vulnerable populations for hepatitis B, hepatitis C, syphilis, and human immunodeficiency virus in Central Brazil.
    PLoS One. 2025;20:e0325859.
    PubMed     Abstract available
    
    
    
21. TORGERSEN J, Newcomb CW, Carbonari DM, Smith SM, et al
    Magnetic resonance evaluation of three-dimensional liver fat fraction by hepatitis C status and associations with inflammatory cytokines.
    PLoS One. 2025;20:e0327668.
    PubMed     Abstract available
    
    
    
22. MILLER LS, Rao A, Tunnell K, Wang YF, et al
    Independent assessment of a point of care HCV RNA test by laboratory analytical testing and a prospective field study in the U.S.
    PLoS One. 2025;20:e0324088.
    PubMed     Abstract available
    
    
    
23. DUO H, You J, Du S, Yu M, et al
    Liver cirrhosis in 2021: Global Burden of Disease study.
    PLoS One. 2025;20:e0328493.
    PubMed     Abstract available
    
    
    
24. MUPEDZA TV, Mhlanga L, Mamutse D, Helikumi M, et al
    Modeling the effects of treatment adherence challenges on the transmission dynamics of hepatitis C virus.
    PLoS One. 2025;20:e0329543.
    PubMed     Abstract available
    
    
    
25. NYGARD ODEH K, Soloy Nilsen H, Gangsoy Kristiansen M, Brekke OL, et al
    Cytokines interferon-gamma- inducible protein 10 and granulocyte-macrophage colony-stimulating factor are associated with psychiatric symptoms in opioid-dependent patients: A cross- sectional study.
    PLoS One. 2025;20:e0324365.
    PubMed     Abstract available
    
    
    
26. JIN Y, Lu R, Wang M, Xu Z, et al
    Analysis of blood screening strategies and their efficacy among voluntary blood donors in a region of East China.
    PLoS One. 2025;20:e0331027.
    PubMed     Abstract available
    
    
    
27. HAN L, Bi L, Li X
    The diagnostic value of decreased levels of inflammatory markers for the state of hepatitis C virus (HCV) infection.
    PLoS One. 2025;20:e0332105.
    PubMed     Abstract available
    
    
    
28. WAGI CR, McDowell R, Wright A, Egan KL, et al
    Navigating Hepatitis C care: Knowledge gaps and access barriers among young women who inject drugs in rural Appalachia.
    PLoS One. 2025;20:e0331849.
    PubMed     Abstract available
    
    
    
29. SHENGELAIA L, Anderson EJ, Butsashvili M, Gulbiani L, et al
    Hepatitis C virus reinfection among people who inject drugs in the country of Georgia and injection-related risk factors: Implications for HCV elimination in the EECA region.
    PLoS One. 2025;20:e0330764.
    PubMed     Abstract available
    
    
    January 2024
30. DARVISHI-KHEZRI H, Karami H, Naderisorki M, Ghazaiean M, et al
    Two risk factors for hypozincemia in diabetic beta-thalassemia patients: Hepatitis C and deferasirox.
    PLoS One. 2024;19:e0284267.
    PubMed     Abstract available
    
    
    
31. KALIBATAS V, Kalibatiene L, Imashpayev D
    Blood donations and donors' profile in Lithuania: Trends for coming back after the COVID-19 outbreak.
    PLoS One. 2024;19:e0297580.
    PubMed     Abstract available
    
    
    
32. KENFACK-MOMO R, Ngounoue MD, Kenmoe S, Takuissu GR, et al
    Global epidemiology of hepatitis C virus in dialysis patients: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0284169.
    PubMed     Abstract available
    
    
    
33. YEN YH, Kee KM, Hu TH, Tsai MC, et al
    Hepatitis B virus-related hepatocellular carcinoma has superior overall survival compared with other etiologies.
    PLoS One. 2024;19:e0290523.
    PubMed     Abstract available
    
    
    
34. DANG X, Hanson BA, Orban ZS, Jimenez M, et al
    Characterization of the brain virome in human immunodeficiency virus infection and substance use disorder.
    PLoS One. 2024;19:e0299891.
    PubMed     Abstract available
    
    
    
35. TADESSE K, Ayalew G, Million Y, Gelaw A, et al
    Hepatitis B and hepatitis C virus infections and associated factors among prisoners in Gondar City, Northwest Ethiopia.
    PLoS One. 2024;19:e0301973.
    PubMed     Abstract available
    
    
    
36. KIMBALL S, Reynoso M, McKnight C, Des Jarlais D, et al
    Hepatitis C treatment outcomes among people who inject drugs experiencing unstable versus stable housing: Systematic review and meta-analysis.
    PLoS One. 2024;19:e0302471.
    PubMed     Abstract available
    
    
    
37. WENDELBOE AM, Naqvi OH, Williams M, Hollen H, et al
    Opioid and other drug use and drug-related mortality as indicators of Hepatitis C and Human Immunodeficiency Virus in Oklahoma.
    PLoS One. 2024;19:e0301442.
    PubMed     Abstract available
    
    
    
38. BASIMANE-BISIMWA P, Koyaweda GW, Ngaiganam E, Vickos U, et al
    Seroprevalence and molecular characterization of viral hepatitis and HIV co-infection in the Central African Republic.
    PLoS One. 2024;19:e0291155.
    PubMed     Abstract available
    
    
    
39. HAGOS YM, Yalew GT, Meles HN, Tsegay E, et al
    Hepatitis B and C viral coinfection and associated factors among HIV-positive patients attending ART clinics of Afar regional state, northeast Ethiopia.
    PLoS One. 2024;19:e0302453.
    PubMed     Abstract available
    
    
    
40. GOLAM RM, Khalil MAF, Shaker OG, Ahmed TI, et al
    The clinical significance of long non-coding RNAs MALAT1 and CASC2 in the diagnosis of HCV-related hepatocellular carcinoma.
    PLoS One. 2024;19:e0303314.
    PubMed     Abstract available
    
    
    
41. PEWKLIANG Y, Thongsri P, Suthivanich P, Thongbaiphet N, et al
    Immortalized hepatocyte-like cells: A competent hepatocyte model for studying clinical HCV isolate infection.
    PLoS One. 2024;19:e0303265.
    PubMed     Abstract available
    
    
    
42. MIURA M, Nishino M, Kawaguchi K, Li S, et al
    Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy.
    PLoS One. 2024;19:e0299424.
    PubMed     Abstract available
    
    
    
43. GEDEFIE A, Debash H, Asmamaw S, Getaneh FB, et al
    Epidemiology of an overlapping and parallel infection of Sexually Transmitted Infections among pregnant women in North-east Ethiopia: Its implication for prevention of mother to child transmission.
    PLoS One. 2024;19:e0300149.
    PubMed     Abstract available
    
    
    
44. NAM DE, Park SJ, Omole S, Um E, et al
    Activated Gab1 drives hepatocyte proliferation and anti-apoptosis in liver fibrosis via potential involvement of the HGF/c-Met signaling axis.
    PLoS One. 2024;19:e0306345.
    PubMed     Abstract available
    
    
    
45. ZEZIULIN O, Kornilova M, Deac A, Morozova O, et al
    Modes of HIV transmission among young women and their sexual partners in Ukraine.
    PLoS One. 2024;19:e0305072.
    PubMed     Abstract available
    
    
    
46. SIAW ADJ, Amugsi J, Owusu-Konadu MAA, Drah ST, et al
    Prevalence and risk factors of Hepatitis C virus infection in the Upper East Region of Ghana; a community-based cross-sectional study.
    PLoS One. 2024;19:e0306292.
    PubMed     Abstract available
    
    
    
47. ATANAW T, Girmay G, Zemene A, Assefa M, et al
    Seroprevalence of hepatitis B and C viruses and some possible associated factors among cancer patients at the Oncology Treatment Center, Gondar, Northwest Ethiopia: A cross-sectional study.
    PLoS One. 2024;19:e0308161.
    PubMed     Abstract available
    
    
    
48. 
    Retraction: Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation.
    PLoS One. 2024;19:e0308579.
    PubMed    
    
    
    
49. MANGALA C, Maulot-Bangola D, Moutsinga A, Okolongo-Mayani SC, et al
    Prevalence and factors associated with transfusion-transmissible infections (HIV, HBV, HCV and Syphilis) among blood donors in Gabon: Systematic review and meta-analysis.
    PLoS One. 2024;19:e0307101.
    PubMed     Abstract available
    
    
    
50. LEE CSJ, Mateu-Gelabert P, Melendez YA, Fong C, et al
    Reduced injection risk behavior with co-located hepatitis C treatment at a syringe service program: The accessible care model.
    PLoS One. 2024;19:e0308102.
    PubMed     Abstract available
    
    
    
51. GUURE C, Dery S, Baptista da Silva C, Asamoah-Adu C, et al
    Situational assessment and epidemiology of HIV, HBV and HCV among people who use and inject drugs in Ghana.
    PLoS One. 2024;19:e0305923.
    PubMed     Abstract available
    
    
    
52. MAZUMDER H, Hossain MF, Shrestha P, Mahmud S, et al
    Prevalence and associated risk factors of current hepatitis C infection among U.S. general population and injection drug users aged 20-59 years: NHANES 2009-2018.
    PLoS One. 2024;19:e0309345.
    PubMed     Abstract available
    
    
    
53. WANG HW, Wang YC, Huang YT, Jiang MY, et al
    All-cause and cause-specific mortality risk among men and women with hepatitis C virus infection.
    PLoS One. 2024;19:e0309819.
    PubMed     Abstract available
    
    
    
54. PHYO Z, Ko K, Ouoba S, Sugiyama A, et al
    Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0307872.
    PubMed     Abstract available
    
    
    
55. CHIU I, Cano D, Leathers M, Turner CM, et al
    HIV and hepatitis C virus infection and co-infection among trans women in San Francisco, 2020.
    PLoS One. 2024;19:e0307990.
    PubMed     Abstract available
    
    
    
56. ASTLEY J, Saralamba S, Poovorawan K, White LJ, et al
    Population and transmission dynamics model to determine WHO targets for eliminating Hepatitis C virus in Thailand.
    PLoS One. 2024;19:e0309313.
    PubMed     Abstract available
    
    
    
57. 
    Retraction: SH2 Modified STAT1 Induces HLA-I Expression and Improves IFN-gamma Signaling in IFN-alpha Resistant HCV Replicon Cells.
    PLoS One. 2024;19:e0313111.
    PubMed    
    
    
    
58. JIANG J, Shiels MS, Rivera D, Ghany MG, et al
    Trends in hepatocellular carcinoma and viral hepatitis treatment in older Americans.
    PLoS One. 2024;19:e0307746.
    PubMed     Abstract available
    
    
    
59. GIRMAY G, Bewket G, Amare A, Angelo AA, et al
    Seroprevalence of viral hepatitis B and C infections among healthcare workers in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0312959.
    PubMed     Abstract available
    
    
    
60. KANOKUDOM S, Poovorawan K, Nilyanimit P, Suntronwong N, et al
    Comparison of anti-HCV combined with HCVcAg (Elecsys HCV Duo immunoassay) and anti-HCV rapid test followed by HCV RNA analysis using qRT-PCR to identify active infection for treatment.
    PLoS One. 2024;19:e0313771.
    PubMed     Abstract available
    
    
    
61. HONGJAISEE S, Khamduang W, Kham-Kjing N, Ngo-Giang-Huong N, et al
    Seroprevalence and associated factors of HIV, syphilis, hepatitis B, and hepatitis C infections among sex workers in Chiangmai, Thailand during easing of COVID-19 lockdown measures.
    PLoS One. 2024;19:e0316668.
    PubMed     Abstract available
    
    
    January 2023
62. HACK B, Sanghavi K, Gundapaneni S, Fernandez S, et al
    HCV universal EHR prompt successfully increases screening, highlights potential disparities.
    PLoS One. 2023;18:e0279972.
    PubMed     Abstract available
    
    
    
63. ZHANG C, Qu Q, Yao Y, Fan X, et al
    Detection of Hepatitis C virus RNA using a novel hybridization chain reaction method that competitively dampens cascade amplification.
    PLoS One. 2023;18:e0268917.
    PubMed     Abstract available
    
    
    
64. YU L, Paski SC, Dodge J, Bambha K, et al
    Effect of dietary branched chain amino acids on liver related mortality: Results from a large cohort of North American patients with advanced HCV infection.
    PLoS One. 2023;18:e0284739.
    PubMed     Abstract available
    
    
    
65. WEATHERLY M, Trivedi A, Chembrolu R, Gupta S, et al
    Maternal infections in pregnancy and the risk of sudden unexpected infant death in the offspring in the U.S., 2011-2015.
    PLoS One. 2023;18:e0284614.
    PubMed     Abstract available
    
    
    
66. YAKOVCHENKO V, Jacob DA, Rogal SS, Morgan TR, et al
    User experience of a hepatitis c population management dashboard in the Department of Veterans Affairs.
    PLoS One. 2023;18:e0285044.
    PubMed     Abstract available
    
    
    
67. AWASTHI A, Katiyar H, Rungta S, Deep A, et al
    Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naive non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).
    PLoS One. 2023;18:e0285725.
    PubMed     Abstract available
    
    
    
68. NAING TS, Yee WW, Aung HT, Oo KY, et al
    The feasibility and acceptability of integrating hepatitis C and HIV diagnostic testing on centralized molecular laboratory platforms in Myanmar.
    PLoS One. 2023;18:e0282585.
    PubMed     Abstract available
    
    
    
69. ZANONI BC, Milford C, Sithole K, Mosery N, et al
    High risk injection drug use and uptake of HIV prevention and treatment services among people who inject drugs in KwaZulu-Natal, South Africa.
    PLoS One. 2023;18:e0281030.
    PubMed     Abstract available
    
    
    
70. D FREIRE I, L Fielding K, A J Moore D
    Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?
    PLoS One. 2023;18:e0286306.
    PubMed     Abstract available
    
    
    
71. KUMAR A, Mahajan H, Chaturvedi S, Kumar A, et al
    Hepatitis C virus seroprevalence among patients enrolled at the opioid substitution therapy center in Bihar: A cross-sectional study.
    PLoS One. 2023;18:e0287333.
    PubMed     Abstract available
    
    
    
72. NARTEY YA, Okine R, Seake-Kwawu A, Ghartey G, et al
    Hepatitis C virus seroprevalence, testing, and treatment capacity in public health facilities in Ghana, 2016-2021; A multi-centre cross-sectional study.
    PLoS One. 2023;18:e0287580.
    PubMed     Abstract available
    
    
    
73. ROSS J, Rupasinghe D, Avihingsanon A, Lee MP, et al
    Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020.
    PLoS One. 2023;18:e0287909.
    PubMed     Abstract available
    
    
    
74. MONTEIRO IP, Azzi CFG, Bilibio JP, Monteiro PS, et al
    Prevalence of sexually transmissible infections in adolescents treated in a family planning outpatient clinic for adolescents in the western Amazon.
    PLoS One. 2023;18:e0287633.
    PubMed     Abstract available
    
    
    
75. HANSOONGNERN P, Pratedrat P, Nilyanimit P, Wasitthankasem R, et al
    An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA.
    PLoS One. 2023;18:e0287694.
    PubMed     Abstract available
    
    
    
76. OGUNBAJO A, Brooks M, Oke T, Martinez O, et al
    Hepatitis C (HCV) among Black and Latino sexual minority men (SMM) in the Southern United States: Protocol of a prospective cohort epidemiological study.
    PLoS One. 2023;18:e0288129.
    PubMed     Abstract available
    
    
    
77. CHU C, Gomes T, Antoniou T, Wong WWL, et al
    The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.
    PLoS One. 2023;18:e0284914.
    PubMed     Abstract available
    
    
    
78. NAGARAJA T, Chen L, Balasubramanian A, Groopman JE, et al
    Correction: Activation of the Connective Tissue Growth Factor (CTGF)-Transforming Growth Factor beta 1 (TGF-beta 1) Axis in Hepatitis C Virus-Expressing Hepatocytes.
    PLoS One. 2023;18:e0290786.
    PubMed     Abstract available
    
    
    
79. THI THU PN, Hoang Van D, Ngo Thi Quynh M, Tran Thi N, et al
    Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study.
    PLoS One. 2023;18:e0290235.
    PubMed     Abstract available
    
    
    
80. SCHULER BA, Bastarache L, Wang J, He J, et al
    Population genetic testing and SERPINA1 sequencing identifies unidentified alpha-1 antitrypsin deficiency alleles and gene-environment interaction with hepatitis C infection.
    PLoS One. 2023;18:e0286469.
    PubMed     Abstract available
    
    
    
81. CHAROENKWAN P, Waramit S, Chumnanpuen P, Schaduangrat N, et al
    TROLLOPE: A novel sequence-based stacked approach for the accelerated discovery of linear T-cell epitopes of hepatitis C virus.
    PLoS One. 2023;18:e0290538.
    PubMed     Abstract available
    
    
    
82. SCHWARZ M, Schwarz C, Burghart L, Pfisterer N, et al
    Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes.
    PLoS One. 2023;18:e0290352.
    PubMed     Abstract available
    
    
    
83. EJAZ S, Paracha RZ, Ejaz S, Jamal Z, et al
    Antibody designing against IIIabc junction (JIIIabc) of HCV IRES through affinity maturation; RNA-Antibody docking and interaction analysis.
    PLoS One. 2023;18:e0291213.
    PubMed     Abstract available
    
    
    
84. YOSHIDA Y, Atsukawa M, Kondo C, Kitamura M, et al
    A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C.
    PLoS One. 2023;18:e0292019.
    PubMed     Abstract available
    
    
    
85. GOINS EC, Wein LE, Watkins VY, Campbell AIK, et al
    Maternal and neonatal outcomes in patients with hepatitis C and intrahepatic cholestasis of pregnancy: The sum of the parts.
    PLoS One. 2023;18:e0293030.
    PubMed     Abstract available
    
    
    
86. HOOD RB, Miller WC, Shoben A, Harris RE, et al
    Maternal hepatitis C virus infection and three adverse maternal outcomes in the United States.
    PLoS One. 2023;18:e0291994.
    PubMed     Abstract available
    
    
    
87. GNANAPANDITHAN K, Ghali MP
    Self-awareness of hepatitis C infection in the United States: A cross-sectional study based on the National Health Nutrition and Examination Survey.
    PLoS One. 2023;18:e0293315.
    PubMed     Abstract available
    
    
    
88. PRINSENBERG T, Illidge J, Zantkuijl P, Bedert M, et al
    Correction: Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study.
    PLoS One. 2023;18:e0295455.
    PubMed     Abstract available
    
    
    
89. YE J, Sun Y, Li J, Lu X, et al
    Distribution pattern, molecular transmission networks, and phylodynamic of hepatitis C virus in China.
    PLoS One. 2023;18:e0296053.
    PubMed     Abstract available
    
    
    
90. WURCEL AG, Guardado R, Grussing ED, Koutoujian PJ, et al
    Racial differences in testing for infectious diseases: An analysis of jail intake data.
    PLoS One. 2023;18:e0288254.
    PubMed     Abstract available
    
    
    January 2021
91. SCHMIDBAUER C, Schwarz M, Schutz A, Schubert R, et al
    Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
    PLoS One. 2021;16:e0252274.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.